Pemziviptadil

**Semantic type:** Pharmacologic Substance

**Definition:** A recombinant fusion protein composed of an analogue of the immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) and elastin-like polypeptide (ELP) biopolymer, with potential vasodilating, anti-inflammatory, and anti-fibrotic activities. Upon administration, pemziviptadil targets, binds to and activates VIP receptor-2 (VPAC2). This dilates blood vessels and lowers blood pressure. Pemziviptadil may also inhibit the production of certain pro-inflammatory mediators, such as tumor necrosis factor-alpha (TNFa), interferon-gamma (IFN-g), interleukin-6 (IL-6) and IL-12, and may protect the lungs against a cytokine storm and inflammation. As cytokines cause the air sacs of the lungs to fill with water, making the sacs impermeable to oxygen, pemziviptadil may protect against pulmonary edema, and restores the barrier function at the endothelial/alveolar interface. This may improve blood oxygenation, respiratory distress, and prevent lung injury. The fusion of VIP analogue to ELP allows the sustained release of the agent. Endogenous VIP binds to both VIP receptor-1 (VPAC1) in the gastrointestinal (GI) tract and VPAC2 in the cardiopulmonary system. The selective binding of pemziviptadil to VPAC2 may reduce GI side effects.

**Synonyms:** - PB 1046 - PB-1046 - PB1046 - PEMZIVIPTADIL - Vasomera